Saudi Gazette reportRIYADH — The Saudi Food and Drug Authority (SFDA) has approved the registration of Pemazyre (Pemigatinib) as a monotherapy for adults with locally advanced or metastatic cholangiocarcinoma.
Keep Up to Date with our Weekly Newsletter
